Zheng’s study included 30 patients with growth hormone-secreting tumors (GH-PAs) and 30 with hormonally inactive pituitary tumors (NFPAs), whereas our study had 50 NFPAs and 10 GH-PAs. This evidence concerns the gene GH1 and pituitary tumor.